• CMS proposes limited coverage of Biogen Alzheimer's drug, only in clinical trials

    11 days ago - By MedCity News

    The Center for Medicare and Medicaid Services proposes covering Biogen Alzheimer's disease drug Aduhelm only for people enrolled in a clinical trial. In explaining this proposal, the agency cited the unclear benefit to patients as well as the documented safety risks associated with the drug, which can be best monitored within the context of a clinical trial.
    Read more ...

     

  • Medicare Proposes to Cover Aduhelm Only for Patients in Clinical Trials

    Medicare Proposes to Cover Aduhelm Only for Patients in Clinical Trials

    11 days ago - By New York Times

    If the preliminary decision is finalized this spring, it would sharply limit the number of patients who use the expensive drug.
    Read more ...

     

  • Medicare plans to restrict access to controversial, pricey Alzheimer's drug Aduhelm to patients in clinical trials

    11 days ago - By STAT

    WASHINGTON - Medicare plans to cover the controversial, pricey Alzheimer's drug Aduhelm, but only for certain patients enrolled in clinical trials, the agency announced on Tuesday.
    The proposed move would likely mean some patients will not be able to access the Biogen drug, which is the first Alzheimer's treatment approved in nearly two decades. Since it got the green light this summer, doctors and scientists have raised questions about whether it actually works, government watchdogs have begun investigating whether the Food and Drug Administration followed proper procedure to approve it...
    Read more ...